Related references
Note: Only part of the references are listed.FcγRIIIa expression is not increased on natural killer cells expressing the FcγRIIIa-158V allotype
Nicolas Congy-Jolivet et al.
CANCER RESEARCH (2008)
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Holly M. Horton et al.
CANCER RESEARCH (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
Wei Yu Lin et al.
BLOOD (2007)
Optimizing engagement of the immune system by anti-timor antibodies: an engineer's perspective
John R. Desjarlais et al.
DRUG DISCOVERY TODAY (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
Severine Loisel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
Thomas F. Tedder et al.
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2006)
Human natural killer cell development
Aharon G. Freud et al.
IMMUNOLOGICAL REVIEWS (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates
Sean K. Kelley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys
Y Vugmeyster et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Fc gamma receptors: Old friends and new family members
F Nimmerjahn et al.
IMMUNITY (2006)
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease
N Yazawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies
M Moxness et al.
CLINICAL CHEMISTRY (2005)
Delineation of multiple subpopulations of natural killer cells in rhesus macaques
RL Webster et al.
IMMUNOLOGY (2005)
CD19 regulates B cell maturation, proliferation, and positive selection in the FDC zone of murine splenic germinal centers
Y Wang et al.
IMMUNITY (2005)
Depletion of B cells by a humanized Anti-CD20 antibody PRO70769 in Macaca fascicularis
Y Vugmeyster et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study
CF Eisenbeis et al.
CLINICAL CANCER RESEARCH (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys
C Schröder et al.
TRANSPLANT IMMUNOLOGY (2003)
CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals
DC Otero et al.
JOURNAL OF IMMUNOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CD19 expression and growth inhibition of tumours in human multiple myeloma
H Ishikawa et al.
LEUKEMIA & LYMPHOMA (2002)
Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons:: depletion of CD20-and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody
IPJ Alwayn et al.
XENOTRANSPLANTATION (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation
P Brams et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
